1. 614TiPUCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis. (23rd October 2018) Authors: Mazard, T; Ghiringhelli, F; Mollevi, C; Assenat, E; Gavoille, C; Smith, D; Pezzella, V; Meddeb, R; Pastor, B; Ychou, M; Thierry, A R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial. Issue 11 (22nd August 2019) Authors: Nougaret, S; Castan, F; Forges, H; Vargas, H A; Gallix, B; Gourgou, S; Rouanet, P; Rullier, E; Lelong, B; Maingon, P; Tuech, J-J; Pezet, D; Rivoire, M; Meunier, B; Loriau, J; Valverde, A; Fabre, J-M; Prudhomme, M; Cotte, E; Portier, G Journal: British journal of surgery Issue: Volume 106:Issue 11(2019) Page Start: 1530 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-099Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients. (2nd July 2019) Authors: Samalin, E; Mazard, T; Assenat, E; Rouyer, M; De la Fouchardière, C; Guimbaud, R; Smith, D; Portales, F; Ychou, M; Fiess, C; de Forges, H; Lopez-Crapez, E; Thézenas, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗